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Iron deficiency affects one quarter of the world’s population and causes significant
morbidity, including detrimental effects on immune function and cognitive development.
Accordingly, the World Health Organization (WHO) recommends routine iron
supplementation in children and adults in areas with a high prevalence of iron deficiency.
However, a large body of clinical and epidemiological evidence has accumulated
which clearly demonstrates that host iron deficiency is protective against falciparum
malaria and that host iron supplementation may increase the risk of malaria. Although
many effective antimalarial treatments and preventive measures are available, malaria
remains a significant public health problem, in part because the mechanisms of malaria
pathogenesis remain obscured by the complexity of the relationships that exist between
parasite virulence factors, host susceptibility traits, and the immune responses that
modulate disease. Here we review (i) the clinical and epidemiological data that describes
the relationship between host iron status and malaria infection and (ii) the current
understanding of the biological basis for these clinical and epidemiological observations.
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Iron deficiency and malaria are significant co-morbidities in large
portions of the developing world, and both maladies dispropor-
tionately affect pregnant women and children. Malaria causes an
estimated 250 million infections and 500,000 deaths annually.
Iron deficiency is estimated to affect one quarter of the world’s
populations causing substantial morbidity. Fortunately, iron defi-
ciency is easily treated with iron supplementation (Okebe et al.,
2011). Accordingly the World Health Organization (WHO) rec-
ommends routine iron supplementation for children and adults
in areas with high prevalence of iron deficiency (Haider et al.,
2013; Low et al., 2013). However, the wisdom of universal
iron supplementation campaigns in malaria endemic regions has
recently been questioned due to clinical evidence that suggests
iron deficiency protects against malaria, and that iron supple-
mentation of women and children may increase the incidence
of malaria when given without malaria prophylaxis or access to
adequate health care (Nyakeriga et al., 2004; Sazawal et al., 2006;
Tielsch et al., 2006; Kabyemela et al., 2008; Senga et al., 2011;
Veenemans et al., 2011; Gwamaka et al., 2012; Jonker et al.,
2012; Esan et al., 2013; Zlotkin et al., 2013). This situation has
created a dilemma for health policy makers and health care work-
ers in malaria endemic regions of the world (Prentice et al.,
2013).
Despite these clinical and epidemiological studies, the extent
to which the human host’s iron status affects risk to and severity
of malaria infection is unknown. Differences in study design and
confounding factors (such as acquired immunity to malaria and
hemoglobinopathies) have made the clinical and epidemiological
studies difficult to interpret (Prentice et al., 2007). Furthermore,
though iron and malaria have been and continue to be studied
the exact biological relationship between host iron and malaria
virulence remains largely unclear.
IRON DEFICIENCY AND IRON DEFICIENCY ANEMIA
Iron deficiency is a condition in which there is insufficient iron
in the body to maintain normal physiologic functions. Iron
deficiency can be categorized into three stages: iron deficiency
without anemia, iron deficiency with mild anemia, and iron defi-
ciency with severe anemia. Iron deficiency anemia occurs when
iron stores are exhausted and the supply of iron to tissue is com-
promised; this condition is defined as anemia with biochemical
evidence of iron deficiency. Iron deficiency is most prevalent and
severe in young children and women of reproductive age, but
can also occur in older children, adolescents, adult men, and
the elderly. It is estimated that 50% of pregnant women and
40% of preschool children in the developing world are iron defi-
cient (WHO | Assessing the iron status of populations, 2007;
Kassebaum et al., 2014). Often, iron deficiency develops slowly
and is not clinically diagnosed until severe anemia is apparent
(Stoltzfus, 2003).
Studies suggest that iron deficiency impairs the growth, cog-
nition, and neurological development of children from infancy
through adolescence, impairs immune function, and is associ-
ated with increased morbidity rates (De-Regil et al., 2011, 2013;
Wang et al., 2013). Iron deficiency during pregnancy is associ-
ated with multiple adverse outcomes for both mother and infant,
including increased risk of hemorrhage, sepsis, maternal mortal-
ity, perinatal mortality, and low birth weight (Peña-Rosas et al.,
2012a,b). Iron deficiency anemia can be a direct cause of death or
contribute indirectly. For example, during child birth an anemic
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mother cannot afford to lose more than 150mL of blood, com-
pared with a healthy mother who can lose up to 1 liter of blood
and still survive. Thus, the WHO recommends iron supplemen-
tation for all men, women, and children in areas where malnu-
trition is prevalent (WHO | Guidelines on food fortification with
micronutrients, 2006).
Host iron metabolism is intimately linked to the host response
to infection and inflammation. In the face of infection and
inflammation, the human host protein hepcidin becomes ele-
vated and initiates signaling which results in reduced iron absorp-
tion into the body along with the redistribution of body iron
stores. As a consequence many of the biomarkers utilized to assess
host iron status are sensitive to both iron as well as infection.
For example, low serum ferritin (serum ferritin reflects total body
iron reservoirs) is indicative of iron deficiency. However, ferritin
is also an acute phase protein which is elevated in the context
of infection, and as a result is not a reliable marker of human
iron status in the presence of infection or inflammation. Like
serum ferritin, transferrin saturation and transferrin receptor lev-
els are biochemical markers of human iron status that are also
sensitive to infection and inflammation. As a result evaluating an
individual’s iron status during an infection has proven difficult
(Aguilar et al., 2012), and the scientific community has struggled
to establish formal guidelines.
MALARIA
In 2012 malaria caused an estimated 207 million infections and
over 600,000 deaths; 90% of these deaths occurred in sub-Saharan
Africa, and 77% occurred in children under five (WHO | World
Malaria Report, 2013). At least five species of the eukaryotic
Apicomplexan parasite from the genus Plasmodium cause malaria
in humans with Plasmodium falciparum being the most com-
mon and deadly. Following the bite of a malaria parasite infected
mosquito, the sporozoite stage of the parasite enters the blood-
stream and travels to the liver, where it subsequently infects liver
hepatocytes. Malaria replication in the liver is asymptomatic.
Next, the merozoite form of the parasite leaves the liver and enters
into circulation to infect host red blood cells (RBCs). During the
erythrocytic stage of infection, the parasite repeatedly invades,
replicates within, and egresses from host RBCs. This erythrocytic
stage of infection is responsible for all symptoms of disease (Miller
et al., 2013), and the severity of disease is directly associated with
parasite burden (Chotivanich et al., 2000; Dondorp et al., 2005).
A wide range of symptoms can be observed inmalaria patients.
Clinically however, malaria is categorized as either uncompli-
cated or complicated. Complicated malaria is further divided into
three overlapping syndromes: cerebral malaria, severe anemia,
and metabolic acidosis. The clinical syndrome observed in each
individual patient is influenced by multiple variables: parasite
species, host immune status, and genetic background, as well as
the use and timing of antimalarial drugs (Taylor et al., 2010).
CLINICAL STUDIES LINKING IRON AND MALARIA
INFECTION
Host iron has received significant attention at the clinical level as
a major factor that may regulate malaria virulence. The results
of clinical studies conducted prior to 2002 which examined
the relationship between host iron status and malaria risk are
reviewed in three meta-analyses (Shankar, 2000; Oppenheimer,
2001; Gera and Sachdev, 2002). In the interim, two large iron sup-
plementation trials as well as several smaller clinical studies have
shed further light on the relationship between host iron status
and malaria infection (Table 1). Clinical trials that have exam-
ined the relationship between host iron and malaria fall into two
basic categories: those that observe the rate of malaria in indi-
viduals with iron deficiency anemia, and those that look at the
rate of malaria infection in individuals given iron supplementa-
tion. Differences in study design exist within both study types,
and include: the definition of study participant iron status, the
administration of iron alone or with folate, and access to health
care. Despite these differences, assessment of the outcome of the
clinical studies has led to the general consensus that iron defi-
ciency is protective against malaria, and iron supplementation
increases malaria risk in the absence of access to adequate health
care (Prentice and Cox, 2012; Spottiswoode et al., 2012; Stoltzfus,
2012).
While these clinical studies andmeta-analyses have been indis-
pensable for determining the relationship between host iron
status and malaria risk, it is not clear how iron deficiency pro-
tects and why iron supplementation increases risk. Immunity to
malaria and high prevalence of genetic traits such as G6PD defi-
ciency and hemoglobinopathies in the study populations limit the
capacity of clinical studies to parse out causation. Furthermore,
relatively little is known with regards to the role host iron plays
in malaria pathogenesis. Iron impacts a broad range of biological
processes that have the potential to shape malaria pathogenesis.
As a result, even with the most ideal of clinical study designs;
the prerequisite knowledge of which aspects of malaria patho-
genesis should be studied is largely absent. A better grasp on
the underlying biological principals that govern (i) the protec-
tion of iron deficiency against malaria and (ii) the increased risk
of malaria associated with iron supplementation is critical for
managing iron supplementation campaigns in malaria endemic
regions.
BIOLOGICAL IMPORTANCE OF IRON
Iron is an essential nutrient for nearly every living organism
including humans and the malaria parasite. Iron impacts a broad
range of biological processes; including host and parasite cellu-
lar function, erythropoiesis and immune function. The capacity
of iron to fluctuate between two oxidation states, ferrous (Fe2+)
and ferric (Fe3+), makes it indispensable for many critical bio-
logical processes, including DNA replication, cellular respiration,
and oxygen transport. However, the same useful biphasic prop-
erties of iron which make it indispensable also contribute to its
high cytotoxicity. As a result the human host tightly regulates iron
availability and usage.
Access to iron is particularly important in the context of
host-pathogen interactions. When confronted with infection and
inflammation the human host reallocates its iron reservoirs in an
effort to deprive invading pathogens of iron. The human pro-
tein hepcidin—a rheostat of systemic iron homeostasis—signals
the body to decrease absorption of iron in the proximal duode-
num and orchestrates the movement of iron from serum into
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Table 1 | Summary of clinical studies on iron deficiency, iron supplementation, and malaria.
References Study design Population Country, malaria info Results
CHILDREN—INTERVENTIONAL STUDIES
Sazawal et al., 2006 Randomized placebo
controlled
7950 children given iron and folic
acid
8120 children given iron, folic acid
and zinc
8006 control children
Ages 1–35 months
Zanzibar, intense malaria
transmission
Trial stopped early because of safety
concerns. Those who received iron and
folic acid with or without zinc were 12%
(95% CI 2–23, p = 0.02) more likely to die
or need hospital treatment for an adverse
event and 11% (95% CI 1–23, p = 0.03)
more likely to be admitted to hospital;
there were also 15% (95% CI 7–41,
p = 0.19) more deaths in these groups
Tielsch et al., 2006 Randomized placebo
controlled
8337 children given iron and folic
acid
9230 children given iron, folic acid
and zinc
8683 control children
Ages 1–36 months
Nepal, no malaria Daily supplementation of young children in
southern Nepal with iron and folic acid
with or without zinc had no effect on their
risk of death, but might protect against
diarrhea, dysentery, and acute respiratory
illness
Veenemans et al.,
2011
2× 2 Factorial trial 145 children given zinc only
148 children given both zinc and
multi-nutrients (including iron)
146 children given multi-nutrients
(including iron) without zinc
148 children given placebo
Ages 6–60 months
Tanzania, intense malaria
transmission
When data was analyzed by iron status at
baseline, multi-nutrient supplementation
increased the overall number of malaria
episodes in children with iron deficiency
by 41%, whereas multi-nutrient
supplementation had no effect on the
number of malaria episodes among
children who were iron-replete at baseline
Zlotkin et al., 2013 Cluster randomized,
double blind
967 children given micronutrient
powder with iron
991 children given micronutrient
powder without iron
Ages 6–35 months
Ghana, intense malaria
transmission
Insecticide treated
bednets provided at
enrollment
Malaria incidence was significantly lower
in the iron group compared with the no
iron group during the intervention period
(risk ratio [RR], 0.87; 95% CI, 0.78–0.96).
In secondary analyses, these differences
were no longer statistically significant after
adjusting for baseline iron deficiency and
anemia status overall (RR, 0.87; 95% CI,
0.75–1.01)
Subgroup analysis of 704 children who
had anemia at baseline and for whom
additional blood samples were obtained at
the end of the intervention period found
only a small mean increase in hemoglobin
in the iron group (mean change of
0.08 g/dL measured), indicating that the
micronutrient powder had limited efficacy
in this trial
Esan et al., 2013 2-arm, double-blind,
randomized
100 children received
multivitamins plus iron
96 children received multivitamins
alone
HIV infected children aged 6–59
months with moderate anemia
(Hgb = 7.0–9.9 g/dL); 3 months of
treatment, 6 months follow up
Malawi, intense malaria
transmission
Children who received iron had a better
CD4 percentage response at 3 months,
but an increased incidence of malaria at 6
months (incidence rate, 120.2 vs. 71.7;
adjusted incidence rate ratio [aIRR], 1.81
[95% CI, 1.04–3.16]; p = 0.04), especially
during the first 3 months (incidence rate,
78.1 vs. 36.0; aIRR, 2.68 [95% CI,
1.08–6.63]; p = 0.03)
(Continued)
www.frontiersin.org May 2014 | Volume 5 | Article 84 | 3
Clark et al. Host iron and malaria
Table 1 | Continued
References Study design Population Country, comments
about malaria
transmission rate
Results
CHILDREN—OBSERVATIONAL STUDIES
Nyakeriga et al.,
2004
2 Cross sectional
studies
Study 1:
Iron replete (n = 95)
Iron deficient (n = 78)
Study 2:
Iron replete (n = 104)
Iron deficient (n = 91)
Ages 8 months-8 years
Kenya, intense malaria
transmission
Incidence of clinical malaria was
significantly lower among children with
iron deficiency anemia (incidence-rate
ratio [IRR], 0.70; 95% confidence interval
[CI], 0.51–0.99; P < 0.05)
Gwamaka et al.,
2012
Longitudinal 785 children monitored for 3 years Tanzania, intense malaria
transmission
Iron deficiency anemia at routine,
well-child visits significantly decreased the
odds of subsequent parasitemia (23%
decrease, p < 0.001) and subsequent
severe malaria (38% decrease, p = 0.04).
Iron deficiency anemia was also
associated with 60% lower all-cause
mortality (p = 0.04) and 66% lower
malaria-associated mortality (p = 0.11)
Jonker et al., 2012 Longitudinal 727 children monitored for 1 year Malawi, intense malaria
transmission
Children with iron deficiency anemia at
baseline had a lower incidence of malaria
parasitemia and clinical malaria during a
year of follow-up; adjusted hazard ratios
0.55 (95% CI:0.41–0.74) and 0.49 (95%
CI:0.33–0.73), respectively
PREGNANT WOMEN—OBSERVATIONAL
Kabyemela et al.,
2008
Cross sectional 445 pregnant women (120
primigravidae, 112
secundigravidae, and 213
multigravidae)
Tanzania, intense malaria
transmission
Iron deficiency decreased the risk of
placental malaria
Senga et al., 2011 Case-Control Pregnant women (112 cases with
placental malaria, 110 controls
with no evidence of placental
infection)
Malawi, intense malaria
transmission
Iron deficiency decreased risk of acute,
chronic and past placental malaria. The
association was greater in the
multigravidae group
storage within the liver and macrophages (Roy, 2013). As a result
of reduced serum iron, erythropoiesis—a process exquisitely sen-
sitive to iron levels—slows in the face of infection as well as
inflammation. The human host’s active reduction in bioavailable
iron protects against a wide range of pathogens (Armitage et al.,
2011). Not surprisingly, as many pathogens require access to host
iron sources to survive and grow, pathogens have evolved sophis-
ticated iron acquisition systems, and the iron acquisition systems
of many bacterial and fungal species have been well described
(Skaar, 2010). By comparison how the malaria parasite acquires,
regulates, and utilizes iron remains a mystery.
IRON METABOLISM IN THE MALARIA PARASITE
Iron is essential for the survival of the malaria parasite. The
parasite multiplies 8–32 times in the course of a single intra-
erythrocytic lifecycle. Iron is an essential cofactor for the DNA
replication enzyme ribonucleotide reductase, and as a result
iron is required to fuel this rapid intra-erythrocytic proliferation
(Rubin et al., 1993). Iron is also utilized by the parasite for pyrim-
idine (Krungkrai et al., 1990; Van Dooren et al., 2006) and heme
biosynthesis (Sato and Wilson, 2002; Dhanasekaran et al., 2004;
Sato et al., 2004; Nagaraj et al., 2008, 2009, 2010, 2013). As with
the human host, the malaria parasite must also balance its need
for iron against the cytotoxicity of iron.
The malaria parasite metabolizes host hemoglobin in its acidic
digestive vacuole in order to acquire necessary amino acids;
however, as discussed below, the parasite does not utilize the
iron in host heme. Plasmodium aspartic and cysteine proteases
degrade host hemoglobin and release large quantities of toxic
iron-laden heme (Goldberg et al., 1990; Subramanian et al.,
2009). Apicoblast parasites neutralize the cytotoxic heme pro-
duced during hemoglobin metabolism by sequestering the heme
in an inert crystal, hemozoin (Rudzinska et al., 1965; Chugh et al.,
2013). Despite neutralizing a substantial portion of host heme
into hemozoin, some residual heme remains free and becomes
oxidized, generating free oxygen radicals (Francis et al., 1997).
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The parasite possesses powerful thioredoxin and glutathione sys-
tems to maintain intracellular redox equilibrium (Jortzik and
Becker, 2012). However, even when these redox systems are func-
tioning at full capacity, oxidative stress significantly increases as
the parasite matures and replicates within host erythrocytes (Fu
et al., 2010). In fact, many antimalarials, including artemisinin,
appear to target the parasite’s ability to detoxify reactive oxy-
gen species (ROS) (Rosenthal and Meshnick, 1996; Klonis et al.,
2013; Ariey et al., 2014). For example, it was recently found that
mutations in PF3D7_1343700 (Kelch) can confer resistance to
artemisinin. The authors speculate that these mutations cause a
disruption of the parasite’s ability to detoxify ROS because the
efficacy of artemisinin depends on its ability to generate oxygen
radicals and some kelch-containing proteins in other organisms
have been shown to be involved in the regulation of cytoprotec-
tion (Ariey et al., 2014).
Given the relationship between iron, heme, and ROS, it is
possible that perturbations in host iron regulation might also
affect the malaria parasite’s redox equilibrium. Iron responsive
proteins (IRPs) and their accompanying iron responsive ele-
ments are critical for maintaining cellular iron homeostasis in
the human host. IRPs and iron responsive elements are respon-
sible for mobilizing iron when demands are high and moving
iron into storage when excess iron may promote ROS formation
(Hentze et al., 2010). Loyevsky et al. identified and characterized
a P. falciparum IRP, the expression of which was affected by iron
starvation as well as iron supplementation (Loyevsky et al., 2001,
2003; Hodges et al., 2005). However, a search of gene databases
failed to identify Plasmodium homologs of ferritin, ferroportin,
metallothione, a ferrioxamine-based transport system or ferre-
doxin or siderophore biosynthesis pathways—all proteins and
processes utilized by other organisms to acquire, regulate, and
store iron (Scholl et al., 2005). Clearly, much remains unknown
regarding parasite iron biology.
IRON CHELATORS AND THEIR CONTRIBUTION TO THE
ELUCIDATION OF MALARIA IRON BIOLOGY
Realizing the importance of iron for the malaria parasite,
researchers have invested extensive time and effort into the inves-
tigation of the antimalarial activity of iron chelating agents. These
studies have also provided insight into malaria parasite iron
biology. In contrast to mammalian cells, which are sensitive to
millimolar concentrations of iron chelators, erythrocytic stage
malaria parasites are sensitive to micromolar concentrations of
iron chelators in vitro and in animal models (Cabantchik et al.,
1996). The cytotoxicity of iron chelators is dependent upon the
stage of intra-erythrocytic maturation of the malaria parasite and
the hydrophobicity of the iron chelator (Lytton et al., 1994). For
example, the hydrophilic chelator hydroxamate-based deferox-
amine (DFO) has cytostatic activity against the ring stage and
cytotoxic activity against the late trophozoite and schizont ery-
throcytic stages of the parasite (Whitehead and Peto, 1990; Lytton
et al., 1994; Cabantchik et al., 1999).
The cytotoxicity of iron chelators against the malaria para-
site suggests that the mechanism of action of iron chelators is
more complex than simple iron deprivation. Alternative mech-
anisms have been suggested for some chelators, including the
direct inhibition of parasite ribonucleotide reductase activity
(Lederman et al., 1984; Lytton et al., 1994). Furthermore, as
iron chelators can modulate host immune function, iron chelator
antimalarial activity may be a result of modification of the host
immune response (Golenser et al., 2006; Li et al., 2012).
Caution must be taken when considering the use of iron chela-
tors to inform our understanding of the biological relationship
between iron deficiency and malaria infection. The evidence that
iron chelators do more than merely deprive the parasite of iron
introduces potential confounding factors into studies that utilize
iron chelators as a model for iron deficiency. Furthermore, most
iron chelators cannot chelate iron associated with heme, ferritin,
or transferrin. Because the iron saturation of each of these host
iron reservoirs are reduced in iron deficiency, iron chelators are
not suitable for studying the effect of host iron reduction on the
malaria parasite.
That said, evidence that chelation of chelatable extracellular
and intra-erythrocyte iron does not impact erythrocytic stage
P. falciparum growth, suggests that chelatable host iron is not
necessary for the erythrocyte stage of infection (Scott et al.,
1990). Furthermore, work byMoormann et al. shows that parasite
nuclear and mitochondrial transcripts decrease in the presence
of the iron chelator DFO (Moormann et al., 1999). These results
are consistent with a normal cellular response to iron depriva-
tion. In conclusion, iron chelators are obviously indispensable in
the study of iron biology. However, in the case of malaria caution
must be taken.
HOST IRON RESERVOIRS AVAILABLE TO ERYTHROCYTIC
STAGE MALARIA
It is inarguable that iron is essential to erythrocytic stage malaria
and therefore possible that alterations in host iron levels may
tip the balance between inhibiting or promoting parasite growth
and virulence. Consequently, the question of how the parasite
acquires host iron becomes central. A healthy iron-replete human
has 3–4 total grams of iron, which is distributed in hemoglobin
contained within circulating RBCs (2.5 g), in iron containing pro-
teins (400mg), in serum bound to transferrin (3–7mg), and in
storage proteins such as ferritin (1 g). Host iron reservoirs avail-
able to erythrocytic stage malaria parasite include: (1) transferrin
and non-transferrin bound iron (NTBI) in the serum and (2)
intra-erythrocytic iron contained within hemoglobin, ferritin, as
well as trace amounts freely bioavailable iron in the RBC cytosol
(Figure 1).
Iron deficiency affects these host iron reservoirs by sig-
nificantly reducing the availability of both serum iron and
intra-erythrocytic iron. Iron supplementation results in brief
spikes in serum iron levels (Schümann et al., 2012, 2013), but
has little immediate effect on intra-erythrocyte iron. However,
approximately 2 weeks following iron supplementation, average
intra-erythrocyte iron levels slowly begin improving as new iron-
replete RBCs enter into circulation. It is well-documented that
virulence of many bacteria is directly associated with the avail-
ability of host iron, and as a result iron supplementation can exac-
erbate infections (Doherty, 2007). Whether described changes in
serum and intra-erythrocyte iron stores affect erythrocytic stage
malaria infection remains unknown.
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FIGURE 1 | Host Iron available to erythrocytic stage P. falciparum. Host
iron immediately available to the erythrocytic stage of P. falciparum include
serum and intra-erythrocytic iron. Serum iron ranges from 10 to 27μM.
Transferrin bound iron is the predominant form of iron in the serum,
though trace amounts of non-transferrin bound iron (NTBI) are present. In
some pathologic conditions such as hemochromatosis, NTBI may be
significantly greater. While iron deficiency anemia is characterized by a
significant decline in serum iron. RBC iron is found within hemoglobin
(20mM), ferritin (0.7 nM), and as bioavailable iron (1–10μM). Iron
deficiency anemia significantly reduces RBC iron, specifically hemoglobin
iron. Shown in the figure are: Pf, P. falciparum; DV, digestive vacuole; N,
parasite nucleus; and EC, endothelial cell.
THE RELATIONSHIP BETWEEN SERUM IRON AND
ERYTHROCYTIC STAGE MALARIA
The relationship between host serum iron and parasitized RBCs
(pRBCs) is especially intriguing (Table 2). Because transferrin
has an extremely high affinity for iron (1023M−1 at pH 7.4),
NTBI is scarce in healthy individuals. There is strong evidence
that transferrin associates with pRBCs but not uninfected RBCs.
Work by Pollack et al. shows that pRBCs take up Fe59 bound
to human transferrin, and a recent publication by our own
group demonstrates that incubation of pRBCs with transfer-
rin and ferric citrate increases the bioavailable iron in pRBCs
(Pollack and Fleming, 1984; Clark et al., 2013). The idea that
the parasite is able to acquire transferrin bound iron is further
supported Surolia et al. who demonstrated that gelonin toxic-
ity toward P. falciparum is 25 times greater when the gelonin is
bound to transferrin (Surolia and Misquith, 1996). Moreover,
Fry et al. report transferrin reductase activity associated with
pRBCs but not uninfected RBCs (Fry, 1989). Additionally, two
groups have reported the identification of a P. falciparum trans-
ferrin receptor in the RBC membrane of pRBCs (Haldar et al.,
1986; Rodriguez and Jungery, 1986). However, a later study by
Pollack et al. concluded that transferrin binding of pRBCs is non-
specific (Pollack and Schnelle, 1988), and additional studies were
unable to detect any acquisition of transferrin bound iron by
pRBCs (Peto and Thompson, 1986; Sanchez-Lopez and Haldar,
1992).
Despite strong evidence that transferrin associates with
pRBCs, neither iron depletion nor iron supplementation of
malaria culture media has any observable effect on parasite
growth (Peto and Thompson, 1986; Scott et al., 1990; Sanchez-
Lopez and Haldar, 1992; unpublished data Clark et al.). These
results challenge the idea that serum iron, specifically transferrin
bound iron, contributes to the protection of iron deficiency from
malaria and the increased risk ofmalaria associated with iron sup-
plementation. Yet, it should be noted that malaria culture media
contains tenfold less iron than human sera and all existing stud-
ies have utilized culture adapted P. falciparum laboratory lines.
It is possible laboratory lines have adapted to an iron-starved
extracellular environment. Furthermore, because hemoglobin is
an essential nutrient for erythrocytic stage malaria, it is impossi-
ble to “starve” the parasite of iron in vitro and this may in turn
limit the ability to study the effect of serum iron on P. falciparum.
THE RELATIONSHIP BETWEEN INTRA-ERYTHROCYTIC IRON
AND ERYTHROCYTIC STAGE MALARIA
Much less is known about the ability of the malaria parasite to
access intra-erythrocytic iron (Table 3). An individual RBC con-
tains 100 fg (20mM) of iron, the majority of which is contained
within hemoglobin. It is estimated that if the parasite were able
to access only 1% of this hemoglobin iron all of its iron demands
would be fulfilled (Hershko and Peto, 1988; Gabay and Ginsburg,
1993). However, as discussed above, the parasite incorporates
the majority of heme released as a result of hemoglobin diges-
tion into hemozoin (Chugh et al., 2013). Despite identification of
a Plasmodium heme oxygenase-like protein, which would facili-
tate release of iron from host heme (Okada, 2009), the parasite
does not exhibit enzymatic heme oxygenase activity nor pos-
sess a canonical heme oxygenase pathway (Sigala et al., 2012).
Even without inherent heme oxygenase activity, it remains pos-
sible that non-enzymatic mechanisms release enough iron from
trace heme to meet the iron requirements of the parasite. Possible
mechanisms include heme breakdown by glutathione or hydro-
gen peroxide, the conditions for which are predicted to exist
within erythrocytic stage parasites (Ginsburg et al., 1998; Loria
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Table 2 | Relationship between host serum iron and P. falciparum.
Study Major findings
STUDIES SUPPORTING TRANSFERRIN MEDIATED DELIVERY OF IRON TO pRBCs
Pollack and Fleming, 1984 - pRBCs take up more iron from transferrin than uninfected RBCs
Rodriguez and Jungery, 1986 - FITC labeled holo-transferrin traverses from the pRBC surface to the parasitophorous vacuole
- Internalization of holo-transferrin is most active in early trophozoite stage pRBCs
- A 93 kD parasite protein inserted into the RBC membrane binds human holo-transferrin
Haldar et al., 1986 - A 102kD schizont stage parasite protein inserted into the RBC membrane binds human holo-transferrin
Pollack and Schnelle, 1988 - Twice as much human holo-transferrin associates with pRBCs than uninfected RBCs
- Human holo-transferrin binding to pRBCs is non-specific
Fry, 1989 - RBC membranes of pRBCs possess diferric transferrin reductase activity, uninfected RBC membranes do not
- pRBC diferric transferrin reductase activity increases as the parasite matures from the ring to trophozoite
stage
Surolia and Misquith, 1996 - Human transferrin conjugated to the toxin gelonin selectively binds trophozoite stage pRBCs
- Toxicity of gelonin to erythrocytic stage P. falciparum is 25 times greater when linked to human transferrin
Clark et al., 2013 - Addition of holo-transferrin to trophozoite stage pRBCs increases the bioavailable iron content of pRBCs but
not uninfected RBCs
STUDIES REFUTING TRANSFERRIN MEDIATED DELIVERY OF IRON TO pRBCs AND STUDIES SHOWING SERUM IRON DOES NOT AFFECT
P. FALCIPARUM GROWTH
Peto and Thompson, 1986 - pRBCs do not acquire iron from holo-transferrin
- Depletion of iron from P. falciparum in vitro culture media does not reduce parasite growth
- Addition of iron to P. falciparum in vitro culture media reduced parasite growth
Scott et al., 1990 - Restriction of iron chelator DFO to P. falciparum in vitro culture media does not affect parasite growth
Sanchez-Lopez and Haldar, 1992 - pRBCs do not take up iron from human holo-transferrin
- Depletion of human transferrin from culture media does not affect erythrocytic stage parasite growth
STUDIES SUPPORTING ACQUISITION OF NTBI BY pRBCs
Peto and Thompson, 1986 - pRBCs take up NTBI
Sanchez-Lopez and Haldar, 1992 - pRBCs take up of free, non-transferrin bound iron (NTBI), but not any more than uninfected RBCs
- pRBC NTBI acquisition is time, concentration, and temperature but not energy dependent
Clark et al., 2013 - Addition of ferric citrate (NTBI) to trophozoite stage pRBCs increases the bioavailable iron content of pRBCs
but not uinfected RBCs
Table 3 | Relationship between RBC iron and P. falciparum.
Study Major findings
RBC HEMOGLOBIN
Rudzinska et al.,
1965
- P. falciparum metabolizes host RBC hemoglobin
- P. falciparum inserts host heme into hemozoin
Okada, 2009 - P. falciparum has a heme oxygenase homolog
Sigala et al., 2012 - P. falciparum lacks both heme oxygenase activity
and a canonical heme oxygenase pathway
Loria et al., 1999 - Hydrogen peroxide degrades host heme under
conditions that are analogous to the
microenvironment of the parasite food vacuole
RBC FERRITIN—UNKNOWN
RBC BIOAVAILABLE IRON—UNKNOWN
et al., 1999). However, as the parasite synthesizes heme de novo, it
does not seem likely that the parasite draws iron from host heme
(Nagaraj et al., 2013).
In addition to hemoglobin, RBCs contain residual amounts of
biovaialble iron (1–10μM) as well as iron stored within ferritin
(0.7 nM), and it is possible that the parasite is capable of utiliz-
ing one or both of these erythrocyte iron reservoirs. Currently,
however, there is no reported evidence to either support or refute
these possibilities (Scholl et al., 2005). However, despite a lack of
evidence that the parasite accesses host intra-erythrocytic iron,
recent work by our group has shown that pRBC bioavailable iron
content increases as the parasite matures from ring stage to sch-
izont. This observation suggests that iron is released from some
form of storage as the parasite develops within host RBCs (Clark
et al., 2013). Whether the iron is released from parasite or host
storage remains an open question.
Although the precise host iron source(s) the malaria para-
site acquires remains unclear, all the potential host iron reser-
voirs (serum and intra-erythrocyte) available to erythrocytic stage
malaria are affected by iron deficiency as well as iron supplemen-
tation. Therefore, it is reasonable to hypothesize that iron depri-
vation and excess iron contribute to the relationship between host
iron and malaria risk observed in the clinical studies discussed
earlier. That said, even during iron deficiency, the erythrocytic
stage of the parasite inhabits the most iron rich environment in
the human body. As such it is alternatively possible that neither
iron deficiency nor iron supplementation perturb iron reservoirs
enough to significantly impact the parasite.
MICROCYTIC IRON DEFICIENT RBCs AND MALARIA
In addition to affecting host iron reservoirs, iron deficiency also
induces changes in RBC physiology. One such difference between
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iron-replete and iron-deficient RBCs is the substitution of zinc
for iron in hemogloblin when iron is limiting. This results in
zinc protoporphoryin IX levels ten times higher in iron deficient
as compared to iron-replete RBCs (Wong et al., 1996). As zinc
protoporphoryin IX inhibits hemozoin extension in vitro; it is rea-
sonable to hypothesize that that elevated zinc protoporphoryin IX
in iron deficient erythrocytes provides protection against malaria
infection by impeding parasite growth (Iyer et al., 2003).
Additional changes to RBC physiology caused by iron defi-
ciency include: microcytosis, greater susceptibility to oxida-
tive stress, reduced ATP content, and decreased deformability
(Yip et al., 1983; Acharya et al., 1991; Nagababu et al., 2008;
Brandão et al., 2009). Furthermore, iron deficient RBCs expe-
rience enhanced eryptotic cell death (Kempe et al., 2006). The
altered physiology of microcytic iron deficient RBCs may there-
fore protect against erythrocytic stage malaria infection. Research
by Koka et al. indicates that propagation of the erythrocytic stage
of P. falciparum strain BinH is reduced in iron deficient RBCs
(Koka et al., 2007). However, earlier work by Luzzie et al. observed
abnormal parasite morphology but no difference in the growth of
P. falciparum strain UPO in iron deficient as compared to iron-
replete RBCs (Luzzi et al., 1990). The differences between these
studies may be explained by the use of different P. falciparum
isolates which feasibly could have different sensitivities to iron
deficient RBCs.
Accelerated host clearance of iron deficient pRBCs is an addi-
tional explanation for the protection afforded by iron deficiency
against malaria. Results from two studies that examined malaria
infection in iron deficient mice both observed a higher clearance
rate of pRBCs in iron deficient as compared to iron-replete mice
(Koka et al., 2007; Matsuzaki-Moriya et al., 2011). Specifically,
Matsuzaki et al. observed elevated phagocytosis of pRBCs in iron
deficient as compared to iron-replete mice, and proposed that
the increased phagocytosis rate may be attributable to greater
phosphatidylserine levels on iron deficient pRBCs as compared
to iron-replete pRBCs. Koka et al. similarly observed greater
phosphatidylserine levels on P. falciparum human iron deficient
pRBCs. Ultimately, these limited data suggests that iron deficiency
may provide protection against malaria infection by both imped-
ing erythrocytic stagemalaria growth and increasing phagocytosis
of iron deficient pRBCs. However, only further investigation will
reveal the true relationship between iron deficient RBCs and
P. falciparum.
PERTURBATIONS IN ERYTHROPOIESIS AND MALARIA
In the absence of sufficient iron for heme synthesis, the human
host’s erythropoietic rate decreases. Conversely, iron supplemen-
tation of individuals with iron deficiency anemia results in a
strong erythropoietic response; because the body attempts to
recover RBC numbers and replace less viable iron deficient RBCs
(Figure 2). It is well-known that P. vivax exclusively infects the
very youngest RBCs (reticulocytes). However, P. vivax is not the
only Plasmodium species that prefers young RBCs. In fact many
species of Plasmodium, including P. falciparum, preferentially
infect young RBCs, and furthermore young RBC support greater
parasite replication than more mature RBCs (Wilson et al., 1977;
Pasvol et al., 1980; Lim et al., 2013). Thus, significant elevation in
the erythropoietic rate could put an individual at increased risk of
erythrocytic stage P. falciparum infection. Tian et al. have investi-
gated this hypothesis in the context of pregnant women, who are
at greater risk of malaria infection than their non-pregnant coun-
terparts and experience increased erythropoietic rates to meet the
FIGURE 2 | Hypothesized impact of iron deficiency anemia and iron
supplementation on P. falciparum erythrocytic infection. Iron deficiency
anemia and iron supplementation each profoundly influence human
erythropoiesis, and this may influence erythrocytic stage malaria infection.
Iron deficiency induced reduction in the erythropoietic rate and synthesis of
microcytic iron deficient RBCs may provide protection against P. falciparum
infection. Conversely, stimulation of the human host’s erythropoietic rate by
iron supplementation and subsequent replacement of microcytic iron
deficient RBCs with young iron-replete RBCs may increase an individual’s risk
of erythrocytic stage P. falciparum infection.
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oxygen demands of the growing fetus. The authors report that
P. falciparum growth is significantly greater in the on average
younger RBCs taken from pregnant women as compared to the
on average older RBCs taken from non-pregnant women (Tian
et al., 1998).
Murine models have additionally been used to shed light
on the relationship between erythropoiesis and malaria infec-
tion. Interestingly, when Chang et al. manipulated the timing
of erythropoiesis during the course of a malaria infection it
was observed that reticulocytosis early in infection significantly
increased infection and morbidity, while reticulocytosis late in
infection decreasedmortality (Chang et al., 2004). These observa-
tions are consistent with recent work by Zhao et al. showing that
lipocalin 2, which is elevated during malaria infection, provides
protection from malaria infection in mice by limiting reticulocy-
tosis (Zhao et al., 2012).
Furthermore, mathematical modeling by Cromer et al. makes
several key predictions that support a role for erythropoiesis in
driving the protection from malaria associated with iron defi-
ciency anemia and increased risk associated with iron supplemen-
tation. First, their model predicts that low reticulocyte production
rate—as would be observed in iron deficiency—in combina-
tion with a parasite that prefers reticulocytes, could result in
a less severe infection. Second, high reticulocyte production—
as would be observed in iron deficient individuals responding
to iron supplementation—could increase severity of malaria
infection (Cromer et al., 2009). These results indicate that lim-
iting reticulocytosis early in infection is important for limit-
ing erythrocytic stage malaria infection and further support
the hypothesis that iron supplementation-induced reticulocytosis
significantly increases the risk of erythrocytic stage P. falciparum
infection.
Together, these observations provide insight into potential
cellular mechanisms contributing to the protection of iron defi-
ciency against malaria, and the increased risk of malaria associ-
ated with iron supplementation. With regard to iron deficiency,
altered RBC physiology may limit P. falciparum propagation
within iron deficient RBCs and increase clearance of iron defi-
cient pRBCs. Furthermore, the reduced erythropoietic rate and
subsequent reduction in an iron deficient individual’s hemat-
ocrit may additionally contribute to protection. Conversely, the
increased erythropoietic rate triggered by iron supplementation
paired with the preference of P. falciparum for young RBCs may
be partially responsible for the increased risk of malaria infection
that is associated with iron supplementation.
CONCLUSIONS AND FUTURE QUESTIONS
Overall, the available evidence supports a link between (i) iron
deficiency and protection from malaria infection and (ii) iron
supplementation and increased risk of malaria. However, there is
still much to be learned. Furthermore, study of the competition
between the malaria parasite and the human host for iron can
serve as a translational model to identify critical molecular mech-
anisms of P. falciparum pathogenesis (see questions in Table 4).
Most importantly, however, such research will help the global
health community reach their goal of devising a strategy for safely
administering iron supplementation in malaria endemic regions.
Table 4 | Questions for future translational research.
PARASITE
How does the malaria parasite regulate iron?
What host iron sources are utilized by the malaria parasite?
Does the malaria parasite store iron?
Are parasite virulence factors regulated by iron?
Can merozoites sense host intra-erythrocytic iron?
RELATIONSHIP BETWEEN PARASITE AND HOST
Is iron limited enough during iron deficiency or in such excess following
iron supplementation to respectively inhibit and exacerbate erythrocytic
stage P. falciparum infection?
Do iron deficiency and iron supplementation affect erythrocytic stage
P. falciparum microvascular adhesion, or host endothelial cell activation?
Do iron deficiency or iron supplementation impact parasite var gene
expression or PfEMP1 protein levels on the RBC membrane?
Are there specific strains of P. falciparum that are better equipped to infect
people with iron deficiency?
What is the effect of host iron deficiency and iron supplementation on
P. falciparum gametocytogenesis?
What are the effects of changing RBC population dynamics on malaria
infection?
How are the host innate and adaptive immune responses to malaria
affected by iron deficiency and iron supplementation?
Is anemia of inflammation protective against malaria?
How does the presence of iron deficiency anemia modify the effects of
HbS, HbC, or HbE on parasite growth, maturation, microvascular adhesion,
or endothelial cell activation?
How do other malaria-protective polymorphisms, such as type O blood
group antigen and glucose-6-phosphate dehydrogenase (G6PD) deficiency,
interact with iron deficiency in mitigating malaria pathogenesis?
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